Docteur Oswald VAN CUTSEM Pneumologue Chef de Service
|
|
|
- Alvin Wiggins
- 9 years ago
- Views:
Transcription
1 Docteur Oswald VAN CUTSEM Pneumologue Chef de Service Contacts secrétariat planning : secrétariat consultations : Diplômes : Doctorat UCL 1983 Diplôme de spécialiste en pneumologie UCL 1988 Mandats Membre de l European Lung Cancer Working Party Membre de la Société Belge de Pneumologie Membre de la Société de Pathologie Thoracique du Nord (France) Membre de la Société de Pneumologie de langue française Membre de l European Respiratory Society Publications VAN CUTSEM O., REMY J., WALLAERT B., TONNEL A.B. Fièvre, douleur et cavité. Rev. Mal. Resp. 1988, 5, 81-83
2 VAN CUTSEM O., MERRILL W.W. Aerobic gram positive infections Current Therapy Disease B.C. Deckers Inc. Toronto. Philadelphia R.M. Cherniak, 372 pages VAN CUTSEM O.,, LEDENT C., MAIRESSE M. Le granulome hyalinisant du poumon. Rev. Mal. Resp. 1990, 7, SCULIER J.-P., PAESMANS M., BUREAU G., DABOUIS G., LIBERT P., VANDERMOTEN G., VAN CUTSEM O., BERCHIER M.-C., RIES F., MICHEL J., SERGYSELS R., MOMMEN P., KLASTERSKY J. Une chimiothérapie hebdomadaire avec de multiples médicaments ou un traitement de chimiothérapie standard : résultats d une étude phase III conduite dans le cancer bronchique à petites cellules par l European Lung Cancer Working Rev. Mal. Resp. 1994, 11 : KLASTERSKY J., SCULIER J.-P., RIES F., DABOUIS G., LIBERT P., SCHMERBER J., THIRIAUX J., BERCHIER M.-C., BUREAU G., VAN CUTSEM O., TAGNON A., SERGYSELS R., MOMMEN P., PAESMANS M. for the European Lung Cancer Working party. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5- fluorouracil. Annals of Oncology 1994, 5 : SCULIER J.-P., PAESMANS M., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL J., VAN CUTSEM O., SCHMERBER J., GINER V., VERCHIER M.-C., SERGYSELS R., MOMMEN P., KLASTERSKY J. for the European Lung Cancer Working party. Long-term survival after chemotherapy containing platinum derivatives in patient with advanced unresectable non small cell lung cancer. Eur. J. Cancer. 1994, 30A : KLASTERSKY J., SCULIER J.-P., RIES F., DABOUIS G., LIBERT P., SCHMERBER J., THIRIAUX J., BERCHIER M.-C., BUREAU G., VAN CUTSEM O., TAGNON A., SERGYSELS R., MOMMEN P., PAESMANS M. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile : a regimen associated with majour toxicity in patients with advance non-small cell lung cancer. SCULIER J.-P., BUREAU G., GINER V., THIRIAUX J., MICHEL J., BERCHIER M.-C., VAN CUTSEM O., KÜSTNER U., KROLL F., MOMMEN P., PAESMANS M., KLASTERSKY J. Induction chemotherapy with ifosfamide, etoposide, ans anthracycline for small cell lung. Experience of the European Lung Cancer Working Sem. Oncol (suppl.2) :
3 PAESMANS M., SCULIER J.-P., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL J., VAN CUTSEM O., SERGYSELS R., MOMMEN P., KLASTERSKY for the European Lung Cancer Working party. Prognostic factors for survival in advance non small cell lung cancer ; uni-and multivariate analyses including recpam analysis in 1052 patients. J. Clin. Oncol : Update pour Classic Papers and Current Comments : 1997, 2 (1) : (Highlights of lung cancer research). SCULIER J.-P., PAESMANS M., BUREAU G., GINER V., LECOMPTE J., MICHEL J., BERCHIER M.-C., VAN CUTSEM O., KÜSTNER U., KROLL F., SERGYSELS R., MOMMEN P., KLASTERSKY Y. for the European Lung Cancer Working A randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small cell cancer. J. Clin. Oncol. 1996, 14 : BORGES M., SCULIERS J.-P., PAESMANS M., LIBERT P., BUREAU G., DABOUIS L., THIRIAUX J., MICHEL J., VAN CUTSEM O., SCHMERBER J., GINER V., BERCHIER M.-C., SERGYSELS R., MOMMEN P., KLASTERSKY J. for the European Lung Cancer Working Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC) Lung Cancer 1996, 16 :21-33 PAESMANS M., SCULIER J.-P., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL J., VAN CUTSEM O., SERGYSELS R., MOMMEN P and KLASTERSKY J. for the European Lung Cancer Working Response to chemotherapy has a discriminant value on the distribution of further survival for patients with advanced non small cell lung cancer : a ten experience of the European lung Cancer Working Eur. J. Cancer 1997, 33 : SCULIER J.-P., PAESMANS M., NINANE V., GINER V., BUREAU G., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN CUTSEM O., RECLOUX P., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., VAN HOUTTE P., KLASTERSKY J., the European Lung Cancer Working Les facteurs pronostiques des cancers bronchiques non à petites cellules au stade avancé : l expérience de l European Lung Cancer Working Rev.. Mal. Resp. 1997, 14 : PAESMANS M., SCULIER J.-P., LECOMPTE J., THIRIAUX J., LIBERT P., SERGYSELS R., BUREAU G., DABOUIS G., VAN CUTSEM O., MOMMEN P., NINANE V., KLASTERSKY J, for the European Lung Cancer Working Prognostic factors for patients with small cell lung cancer : long-term experience of the European Lung Cance Working In «Cancers bronchopulmonaires» (MILLERON B., DEPIERE A.), ARNETTE, VELIZY- VILLACOUBLAY, 1998, pp SCULIER J.-P., PAESMANS M., NINANE V., GINER V., BUREAU G., LAFITTE J.-J. BAUMOHL J., THIRIAUX J., CAN CUTSEM O., RECLOUX P., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., VAN HOUTTE P., KLASTERSKY J., the European Lung Cancer Working
4 Evaluation of the TN sub-staging in patients with initially unresectable stage III non small cell lung cancer treated by induction chemotherapy. Lung cancer, 1998, 22 : SCULIER J.-P., PAESMANS M., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN CUTSEM O., RECLOUX P., BUREAU G., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., BOSSCHAERTS T., BERGHMANS T., VAN HOUTTE P., NINANE V., KLASTERSKY J. - the European Lung Cancer Working A randomised phase III trial comparing further chemotherapy to chest irradiation in objectively responding patients with initially unresectable locoregional non-small cell lung cancer treated by induction chemotherapy. Annals of Oncology : SCULIER J.-P., PAESMANS M., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN CUTSEM O., RECLOUX P., BUREAU G., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., BOSSCHAERTS T., BERGHMANS T., VAN HOUTTE P., NINANE V., KLASTERSKY J. - the European Lung Cancer Working Prognostic factors analysis for response to chemotherapy and survival in a prospective cohort of patients with unresectable locoregional non small cell lung cancer initially treated by induction chemotherapy. Rev. Oncologia 1999, 1, PAESMANS M., SCULIER J.-P., LECOMTE J., THIRIAUX J., LIBERT P., SERGYSELS R., BUREAU G., DABOUIS G., VAN CUTSEM O., MOMMEN P., NINANE V., KLASTERSKY J. for the European Lung Cancer Working Prognostic factors for pataients with small cell lung cancer : analysis of a serie of 763 patients included in 4 consecutive pospective trials and with a minimum follow-up of 75 years. Cancer 2000, 89 : SCULIER J.-P., PAESMANS M., LECOMTE J., VAN CUTSEM O., LAFITTE J.-J., BERGHMANS T., KOUMAKIS G., FLORIN M.-C., THIRIAUX J., MICHEL J., GINER V., BERCHIER M.-C., MOMMEN P., NINANE V., KLASTERSKY J. for the European Lung Cancer Working A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer 2001, 88 : SCULIER J.-P., BERGHMANS T, LAFITTE J.-J., RICHEZ M., RECLOUX P., VAN CUTSEM O., NINANE V., MOMMEN P., PAESMANS M., KLASTERSKY J. for the European Lung Cancer Working A phase III study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung cancer, :
5 SCULIER J.-P, LAFITTE J.-J., LECOMTE J., BERGHMANS T., THIRIAUX J., VAN CUTSEM O., EFREMIDIS A., NINANE V., PAESMANS M., MOMMEN P., KLASTERSKY for the European Lung Cancer Working A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Annals of Oncology, 2002,
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
Activity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
Scottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
SMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:
Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer
EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1
COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize
Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board
Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board Abstract Introduction Management of stage III non small-cell lung cancer (NSCLC) is complex and requires careful work-up, staging,
Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide
Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
Prior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
London Cancer. Mesothelioma Lung Protocols
London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta
Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer
J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,
Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); [email protected] Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
Cancer de Primitif Inconnu (CAPI)
Cancer de Primitif Inconnu (CAPI) Cancer of Unknown Primary origin (CUP) Vincent Berry (Lille) 23/01/2015 Dirigé par le Dr PENEL Définitions Définitions Epidémiologie Anatomo pathologie Explorations Pronostic
Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
Report on New Patented Drugs - Alimta
Report on New Patented Drugs - Alimta Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive
4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used:
4.8 Lung cancer 4.8.1 In 2005, both NICE (National Institute for Health and Clinical Excellence) and SIGN (Scottish Intercollegiate Guidelines Network) published guidelines on the management of lung cancer.
Thrombose associée au cancer. Prévention et traitement. Guy Meyer Université Paris Descartes Hopital Europeen Georges Pompidou, Paris, France
Thrombose associée au cancer Prévention et traitement Guy Meyer Université Paris Descartes Hopital Europeen Georges Pompidou, Paris, France Conflits d intérêt G Meyer Investigateur: Bayer, Daichi-Sankyo,
Chapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
POLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
Targeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014
Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!
What is the reference cytotoxic regimen in advanced gastric cancer?
What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.
Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer
Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer Michael Stokes United BioSource Corporation ISPOR 13 th Annual International Meeting Toronto,
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
Recruiting now. Could you help by joining this study?
Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate
Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
Special Article. Received 5 December 2014; revised 18 February 2015; accepted 25 February 2015. Practical Radiation Oncology (2015) 5, 141-148
Practical Radiation Oncology (2015) 5, 141-148 www.practicalradonc.org Special Article Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society
Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8
Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total
the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 [email protected] Brussels, March 7, 2009
Mesothelioma: The standard of care [email protected] Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
Post-operative intrapleural chemotherapy for mesothelioma
Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy
La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
Small Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
Treatment of Stage III Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of
L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
Lung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
Avastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
Erlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche
Erlotinib for the treatment of non-small cell lung cancer Report from the Decision Support Unit in response to additional data submitted by Roche 10 th January 2008 Part 1: A Sutton. Critique of the network
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline An ASCO Endorsement of Treatment of Small Cell Lung Cancer:
Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with
REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group Educational session Treatment of stage III non-small cell lung cancer (NSCLC) in
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
SAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
Summary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
Avastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
How To Know If You Have Small Cell Lung Cancer
Lung cancer Lung cancer TABLE 85 1. MALIGNANT PULMONARY NEOPLASMS INCIDENCE (%) Common 99 Non small cell lung cancer ~75 Adenocarcinoma ~35 Squamous cell carcinoma ~30 Large cell carcinoma ~10 Small cell
SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years
Appendix A. Search Strategy for Systematic Reviews and Cost-Effectiveness Analyses (Search #1) TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS):
